ReviewDiagnostics (Basel, Switzerland)2023
Adenomyosis and Its Possible Malignancy: A Review of the Literature.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 18 citations in OpenAlex.
- Development and validation of a clinical prediction model for the success of focused ultrasound ablation system for the treatment of adenomyosis.Scientific reports · 2026Article
- Correlations Between Ultrasound Features and Histological Findings in Adenomyosis: A Single-Center Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Pregnancy Complications in Uterine Anomalies-A Pilot Study.Journal of clinical medicine · 2026Article
- Coexistence of gynecological pathology with endometriosis and adenomyosis.Molecular and clinical oncology · 2026Article
- Adenomyosis as a prognostic factor in ovarian cancer: a retrospective study.Archives of gynecology and obstetrics · 2025Article
- Evaluating the Cost-Effectiveness of Cervical Cancer Screening and Treatment in Western Romania.Current oncology (Toronto, Ont.) · 2025Article
- Adenomyosis and endometrial cancer: determining its role as a biological contributor or incidental coexistence.BMC cancer · 2025Article
- Endometriosis: An Immunologist's Perspective.International journal of molecular sciences · 2025Review
- Uterine Artery Embolization as an Alternative Therapeutic Option in Adenomyosis: An Observational Retrospective Single-Center Study.Journal of clinical medicine · 2025Article
- Transcriptomic-based analysis of endometrial tissues from adenomyosis patients reveals significant inflammation biomarkers: A bioinformatics study.International journal of reproductive biomedicine · 2025Article
- Birth Outcomes in Pregnancies with Uterine Malformations: A Single-Center Retrospective Study.Journal of clinical medicine · 2025Article
- Gastric Adenomyoma: A Rare Entity Mimicking Pyloric Neoplasia-A Case Report.Case reports in medicine · 2025Article
- Circular RNAs in endometriosis analyzed through RNA sequencing and bioinformatics for expression profile.PeerJ · 2025Article
- Analysis and validation of novel biomarkers related to palmitoylation in adenomyosis.Frontiers in genetics · 2025Article
- A newly identified allelic mutation c.110C>T in theGynecology and pelvic medicine · 2025Article
- Retrospective study of the factors involved in the development of adenomyosis and theMedicine and pharmacy reports · 2024Article
- Article
- A rare case of concomitant endometrioid adenocarcinoma arising from uterine adenomyosis and clear cell carcinoma arising from parametrial deep endometriosis.BMC women's health · 2024Article
- Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study.iScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer arising from adenomyosis is very rare, with transformation occurring in only 1% of cases and in older individuals. Adenomyosis, endometriosis and cancers may share a common pathogenic mechanism that includes hormonal factors, genetic predisposition, growth factors, inflammation, immune system dysregulation, environmental factors and oxidative stress. Endometriosis and adenomyosis both exhibit malignant behaviour. The most common risk factor for malignant transformation is prolonged exposure to oestrogens. The golden standard for diagnosis is histopathology. Colman and Rosenthal emphasised the most important characteristics in adenomyosis-associated cancer. Kumar and Anderson emphasised the importance of demonstrating a transition between benign and malignant endometrial glands in cancer arising from adenomyosis. As it is very rare, it is difficult to standardize treatment. In this manuscript, we try to emphasize some aspects regarding the management strategy, as well as how heterogenous the studies from the literature are in terms of prognosis in both cancers that develop from adenomyosis or those that are only associated with adenomyosis. The pathogenic mechanisms of transformation remain unclear. As these types of cancer are so rare, there is no standardised treatment. A novel target in the diagnosis and treatment of gynaecological malignancies associated with adenomyosis is also being studied for the development of new therapeutic concepts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.